Mechanisms of Sleep Disruption Hyperalgesia

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2018

Study Completion Date

March 12, 2019

Conditions
Sleep DeprivationPain
Interventions
DRUG

Morphine

0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).

DRUG

Saline Placebo

Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).

BEHAVIORAL

Forced Awakenings

Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.

BEHAVIORAL

Uninterrupted Sleep

Participants will receive an 8 hour period of undisturbed sleep

Trial Locations (1)

21224

Johns Hopkins University Bayview Medical Center, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT01794689 - Mechanisms of Sleep Disruption Hyperalgesia | Biotech Hunter | Biotech Hunter